www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/ARIAD_to_Webcast_Presentation_at_the_Jefferies_2nd_Annual_Healthcare_Conference_742739ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2nd Annual Healthcare Conference in New York, New York. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide ...http://www.finanzen.net/nachricht/ARIAD_to_Webcast_Presentation_at_the_Jefferies_2nd_Annual_Healthcare_Conference_742739http://www.finanzen.net/nachricht/ARIAD_Announces_Webcast_of_Its_Annual_Stockholders_Meeting_737100ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders on June 12, 2008 will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at http://www.ariad.com. ...http://www.finanzen.net/nachricht/ARIAD_Announces_Webcast_of_Its_Annual_Stockholders_Meeting_737100http://www.finanzen.net/nachricht/ARIAD_Appoints_Former_Bristol_Myers_Squibb_Executive_to_Lead_Corporate_Legal_and_Compliance_Functions_732404ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Raymond T. Keane, Esq., to the newly created position of vice president, general counsel and chief compliance officer. Mr. Keane, who most recently was ...http://www.finanzen.net/nachricht/ARIAD_Appoints_Former_Bristol_Myers_Squibb_Executive_to_Lead_Corporate_Legal_and_Compliance_Functions_732404http://www.finanzen.net/nachricht/ARIAD_Initiates_Phase_1_Clinical_Trial_of_its_Investigational_Oral_Multi_Targeted_Kinase_Inhibitor_AP24534_in_Patients_with_Hematological_Cancers_730038ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a Phase 1 clinical trial of its investigational oral multi-targeted kinase inhibitor, AP24534, in patients with refractory hematological cancers, including ...http://www.finanzen.net/nachricht/ARIAD_Initiates_Phase_1_Clinical_Trial_of_its_Investigational_Oral_Multi_Targeted_Kinase_Inhibitor_AP24534_in_Patients_with_Hematological_Cancers_730038http://www.finanzen.net/nachricht/ARIAD_to_Present_Clinical_Data_at_ASCO_on_the_Anti_Tumor_and_Safety_Profile_of_Its_Oral_Investigational_mTOR_Inhibitor_Deforolimus_726701ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of an open-label, Phase 1 multi-center, dose-ranging study of oral deforolimus, showing consistency with results observed in previous studies of intravenous deforolimus. ...http://www.finanzen.net/nachricht/ARIAD_to_Present_Clinical_Data_at_ASCO_on_the_Anti_Tumor_and_Safety_Profile_of_Its_Oral_Investigational_mTOR_Inhibitor_Deforolimus_726701http://www.finanzen.net/nachricht/ARIAD_Reports_First_Quarter_2008_Financial_Results_720842ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the quarter ended March 31, 2008 and provided an update on corporate developments. "Since the beginning of the year, we have remained focused on ...http://www.finanzen.net/nachricht/ARIAD_Reports_First_Quarter_2008_Financial_Results_720842http://www.finanzen.net/nachricht/ARIAD_to_Participate_at_the_Leerink_Swann_Cancer_Roundtable_Conference_718199ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Swann Cancer Roundtable Conference titled Conquering Cancer with Novel Therapeutics, to be held at The Grand Hyatt in New York, New York ...http://www.finanzen.net/nachricht/ARIAD_to_Participate_at_the_Leerink_Swann_Cancer_Roundtable_Conference_718199http://www.finanzen.net/nachricht/ARIAD_to_Webcast_Conference_Call_on_First_Quarter_2008_Financial_Results_716753ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) will hold a live webcast of its quarterly conference call at 8:00 a.m. (ET) on Wednesday, May 7, 2008. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior ...http://www.finanzen.net/nachricht/ARIAD_to_Webcast_Conference_Call_on_First_Quarter_2008_Financial_Results_716753http://www.finanzen.net/nachricht/Preclinical_Data_on_ARIAD_s_Novel_Investigational_mTOR_Inhibitor_Deforolimus_to_Be_Presented_at_the_AACR_Annual_Meeting_704905ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new preclinical data on deforolimus, ARIAD’s mTOR inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, ...http://www.finanzen.net/nachricht/Preclinical_Data_on_ARIAD_s_Novel_Investigational_mTOR_Inhibitor_Deforolimus_to_Be_Presented_at_the_AACR_Annual_Meeting_704905http://www.finanzen.net/nachricht/ARIAD_to_Webcast_Presentation_at_the_Lehman_Brothers_11th_Annual_Global_Healthcare_Conference_692387ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Lehman Brothers 11th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel in Miami, Florida. Harvey J. Berger, M.D., ...http://www.finanzen.net/nachricht/ARIAD_to_Webcast_Presentation_at_the_Lehman_Brothers_11th_Annual_Global_Healthcare_Conference_692387